Regeneron Named to Dow Jones Best-in-Class World Index for Seventh Consecutive Year
Regeneron has been named to the Dow Jones Best-in-Class World Index for global responsibility for the seventh consecutive year, as one of eight biotechnology firms globally and four on the North America index. The company will offer its new gene therapy for congenital hearing loss free in the United States.
1. Dow Jones Best-in-Class Recognition
Regeneron Pharmaceuticals secured placement in the Dow Jones Best-in-Class World Index for the seventh consecutive year, distinguishing itself as one of only eight biotechnology companies worldwide and one of four in the North America index. This recognition underscores the company’s sustained leadership in corporate sustainability and responsibility.
2. Free Gene Therapy for Congenital Hearing Loss
The company announced it will provide its newly approved gene therapy for a specific form of congenital hearing loss at no cost in the United States. This initiative reflects Regeneron’s commitment to expanding patient access to breakthrough treatments and reinforces its strategy of integrating societal benefit into its business model.
3. Science-Led 2030 Responsibility Goals
Regeneron unveiled new science-led responsibility goals through 2030, building on nearly all targets met in its 2025 Responsibility Report. These objectives span ethical innovation, environmental stewardship and community engagement, aiming to drive sustainable growth while advancing global health and corporate responsibility.
4. ESG Performance and Philanthropic Initiatives
Regeneron ranks in the top 10% of its industry across S&P Global, Sustainalytics and ISS ESG ratings and has earned repeated recognition for sustainable practices. The company has also committed $300 million through 2036 to STEM-Fueled™ programs, which have delivered over four million educational experiences to students since 2020.